| 1. |
Vairo F, Federhen A, Baldo G, et al. Diagnostic and treatment strategies in mucopolysaccharidosis Ⅵ[J]. Appl Clin Genet, 2015, 8: 245-255. DOI: 10.2147/TACG.S68650.
|
| 2. |
Valayannopoulos V, Nicely H, Harmatz P, et al. Mucopolysaccharidosis Ⅵ[J]. Orphanet J Rare Dis, 2010, 5: 5. DOI: 10.1186/1750-1172-5-5.
|
| 3. |
Harmatz P, Shediac R. Mucopolysaccharidosis Ⅵ: pathophysiology, diagnosis and treatment[J]. Front Biosci (Landmark Ed), 2017, 22: 385-406.
|
| 4. |
Ferrari S, Ponzin D, Ashworth JL, et al. Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis[J]. Br J Ophthalmol, 2011, 95(5): 613-619. DOI: 10.1136/bjo.2010.179937.
|
| 5. |
Ganesh A, Bruwer Z, Al-Thihli K. An update on ocular involvement in mucopolysaccharidoses [J]. Curr Opin Ophthalmol, 2013, 24(5): 379-388. DOI: 10.1097/ICU.0b013e3283644ea1.
|
| 6. |
Summers CG, Fahnehjelm KT, Pitz S, et al. Systemic therapies for mucopolysaccharidosis: ocular changes following haematopoietic stem cell transplantation or enzyme replacement therapy-a review[J]. Clin Exp Ophthalmol, 2010, 38(Suppl 1): 34-42.
|
| 7. |
Aldenhoven M, Jones SA, Bonney D, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines[J]. Biol Blood Marrow Transplant, 2015, 21(6): 1106-1109. DOI: 10.1016/j.bbmt.2015.02.011.
|
| 8. |
Pitz S, Ogun OL. Does enzyme replacement therapy influence the ocular changes in type Ⅵ mucopolysaccharidosis?[J]. Graefe’s Arch Clin Exp Ophthalmol, 2009, 247(7): 975-980. DOI: 10.1007/s00417-008-1030-1.
|
